Coherus BioSciences (CHRS) Defended at Citi, Analyst Says Buy Weakness - Bloomberg
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $2.13 -2.29%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) Defended at Citi, Analyst Says Buy Weakness - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
- Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
- Li Auto Inc. (LI) Mentioned Positively at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Trader TalkRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
